Tarceva Cleared By Japanese Regulators For NSCLC
This article was originally published in PharmAsia News
Executive Summary
Tarceva (erlotinib) will launch in Japan in early 2008 after being approved by the Japanese Ministry of Health for the treatment of patients with nonresectable, recurrent and advanced non-small cell lung cancer aggravated following chemotherapy, Roche/OSI announced Oct. 22
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)